ArticleEpilepsy & behavior reports2026
Implementation of a ketogenic diet clinic in Mexico: A pilot program in a resource-limited setting.
Article in Epilepsy & behavior reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study describes the implementation and outcomes of the first protocolized Ketogenic Diet Clinic (KDC) in Mexico for pediatric drug-resistant epilepsy (DRE). We conducted a retrospective analysis of 20 patients with DRE who initiated KDT between July 2022 and July 2024 in a multidisciplinary KDC at a public tertiary hospital. All patients were newly started on KDT under a structured protocol; none followed a classic 4:1 ketogenic diet, all received modified regimens. Clinical, nutritional, and socioeconomic data were collected. Seizure outcomes were categorized by percent reduction, and antiseizure medication (ASM) burden was evaluated through changes in cumulative daily dose and ASM count. Hospital admissions were recorded, and caregivers were asked about barriers to implementation. At the first follow-up visit (≈3 months), with complete data for all 20 patients, 10/20 (50 %) achieved ≥50 % seizure reduction and 4/20 (20 %) achieved ≥90 % reduction. Due to staggered recruitment, later visits included fewer patients (n = 18 and n = 14). Among the 14 patients who reached the third visit, 9/14 (64 %) achieved ≥90 % reduction. ASM dose decreased in 12/20 (60 %), and ASM count decreased in 6/20 (30 %). Hospital visits declined from 16 events the prior year to 4 after KDT initiation. Despite cultural, nutritional, educational, and access-related barriers, no patient discontinued the diet, as treatment plans were adapted to maintain feasibility. A structured KDC is feasible and clinically beneficial in a resource-limited setting. Modified KDT regimens reduced seizure burden and treatment intensity, supporting expansion of KDT programs in low-resource contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.